US2017152253A1PendingUtilityA1

Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV

Assignee: JANSSEN PHARMACEUTICALS INCPriority: Mar 16, 2010Filed: Feb 10, 2017Published: Jun 1, 2017
Est. expiryMar 16, 2030(~3.6 yrs left)· nominal 20-yr term from priority
C07C 69/757C07C 215/20C07C 205/57C07D 491/22C07C 235/82C07C 61/06C07D 417/04C07C 67/03C07C 215/30C07D 309/30C07C 235/40C07C 67/31C07B 2200/07C07C 317/44C07D 251/30C07D 417/14C07C 255/57C07C 2601/08C07D 251/28C07C 51/412C07C 51/02C07C 201/12C07C 231/12C07C 51/43C07D 491/18C07C 51/487C07C 69/74
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A process for preparing [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, by the resolution of racemic 4-oxo-1,2-cyclopentanedicarboxylic acid (V), said process comprising: (a) reacting 4-oxo-1,2-cyclopentanedicarboxylic acid (V) with brucine or (1R,2S)-(−)-ephedrine, thus preparing the bis-brucine or bis-(1R,2S)-(−)-ephedrine salt of (V), and (b) precipitating selectively the bis-brucine or bis-(1R,2S)-(−)-ephedrine salt of (1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, while the bis-brucine or bis-(1R,2S)-(−)-ephedrine salt of [(1S,2S)-4-oxo-1,2-cyclopentanedicarboxylic acid stays in solution; (c) liberating the acid II by removal of brucine or (1R,2S)-(−)-ephedrine from the precipitated salt obtained in step (b).

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . The [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid salt with brucine (1:2), having the structure III. 
     
     
         5 . The [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid salt with (1R,2S)-(−)-ephedrine (1:2), having the structure IV. 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . A compound of formula X: 
       
         
           
           
               
               
           
         
         wherein Bn is benzyl. 
       
     
     
         11 . A compound of formula XI: 
       
         
           
           
               
               
           
         
         wherein Bn is benzyl and Quin is as defined in  claim 8 . 
       
     
     
         12 . A compound of formula XII: 
       
         
           
           
               
               
           
         
         wherein Quin is as defined in  claim 8 . 
       
     
     
         13 . A compound of formula XIII: 
       
         
           
           
               
               
           
         
         wherein Quin is as defined in  claim 8 . 
       
     
     
         14 . A compound of formula XIV: 
       
         
           
           
               
               
           
         
         wherein Quin is as defined in  claim 8 . 
       
     
     
         15 . A compound of formula XIX: 
       
         
           
           
               
               
           
         
         wherein R 2  is hydrogen, C 1-4 alkyl, aryl, halogen, —SO 2 —C 1-4 alkyl, CN, or NO 2 . 
       
     
     
         16 . A compound of formula XX: 
       
         
           
           
               
               
           
         
         wherein R 2  is hydrogen, C 1-4 alkyl, aryl, halogen, —SO 2 —C 1-4 alkyl, CN, or NO 2 . 
       
     
     
         17 . A compound of formula XXI: 
       
         
           
           
               
               
           
         
         wherein R 2  is hydrogen, C 1-4 alkyl, aryl, halogen, —SO 2 —C 1-4 alkyl, CN, or NO 2 . 
       
     
     
         18 . The compound of  claim 15 ,  16  or  17 , wherein in the compound of formula XIX, respectively XX or XXI, R 2  is 4-NO 2 .

Join the waitlist — get patent alerts

Track US2017152253A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.